Kornimate/medical-research-clean huggingface dataset:
correlation of gene abnormalities and clinical manifestations of aniridia

Conditions: Aniridia

Summary: this study will examine specific gene changes in patients with aniridia, a disease in which the iris (colored part of the eye) is absent or partially absent, and will correlate the changes with clinical manifestations of the disease. in aniridia, the eye often appears to have no color, but only a larger than normal pupil. patients may have impaired vision and cataracts, glaucoma, nystagmus (rapid, involuntary eye movements), photophobia (light sensitivity), displaced lens, underdeveloped retina, and thickened cornea. this study will focus particularly on corneal changes. patients 4 years old and older with aniridia may be eligible for this study. candidates are screened with a family history and complete eye examination, including the following: * visual acuity testing using a vision chart. * eye pressure measurement. * fundus photography to examine the back of the eye: the pupils are dilated and special photographs of the inside of the eye are taken to evaluate the retina and measure changes that may occur over time. the camera flashes a bright light into the eye for each picture. * slit lamp examination: evaluation of the front part of the eye with a special microscope called a slit lamp biomicroscope. * corneal thickness measurement. participants have blood drawn for genetic testing related to aniridia. relevant medical information, including disease severity and complications, is obtained over time. family members may also be requested to provide blood samples for genetic testing.

this project, phenotype-genotype correlation in aniridia, will study the specific mutations in patients with aniridia and attempt to make a phenotype-genotype correlation. specifically, the study will determine whether specific mutations are more prevalent in aniridic patients who have a predominant involvement of the corneal epithelium. a blood sample will be collected from each individual for isolation of dna and the pax6 gene will be sequenced and analyzed. the principal investigator is brian brooks and the associated investigators are james fielding hejtmancik at the omgs/ogvfb/nei and chi-chao chan, li/nei. associate investigators at collaborating institutions include edward holland (university of cincinnati) and ali djalilian (university of illinois, chicago).

Eligibility criteria:
* patients that meet diagnostic criteria for aniridia will be recruited from the nei and collaborating clinics. while diagnosis of aniridia is not expected to create significant difficulty, every attempt will be made to document the clinical status of each family member included in the study, and to document the clinical syndrome in at least one affected individual by slit lamp photography. a total of 100 subjects will be recruited for this study. there are no specific exclusion criteria other than young age (less than 4 years old) which may pose difficulty in obtaining blood.

Keywords: aniridia pax6 keratopathy limbal stem cell deficiency molecular genetics
behavioral activation and medication optimization for perioperative mental health feasibility study

Conditions: Older Adults; Anxiety; Depression; Cardiac Surgery; Orthopedic Surgery; Major Surgical Resection of a Thoracic Malignancy; Major Surgical Resection of an Abdominal Malignancy

Summary: inadequate management of preoperative mental health disorders often contributes to poor postoperative outcomes, including increased rates of readmission, delirium, falls, and mortality. however, very little work has been done to improve perioperative mental health. in particular, there have been limited systematic efforts that identify evidence-based behavioral and pharmacological strategies that were originally developed for depression and anxiety in otherwise medically well psychiatric patients. a mental health intervention bundle, composed of behavioral and pharmacological strategies, can mitigate anxiety and depression symptoms during the perioperative period. however, lacking is conclusive evidence on effectiveness of such an intervention bundle focused on the delivery of perioperative mental health care in older surgical patients. towards this end, the investigators will develop and test an intervention bundle that encompasses: (1) behavioral activation, and (2) medication optimization.

the proposed research is relevant to public health because the prevalence of undertreated depression/anxiety in older adults coupled with the increasing number of surgeries performed in this population are creating a crucial need for the integration of mental health interventions into critical periods, such as the perioperative period. thus, the proposed research is relevant to the mission of the nimh to transform the treatment of mental illnesses through clinical research, paving the way for prevention, recovery, and cure.

Eligibility criteria:
inclusion criteria patient participants * age ≥60 years on the day of surgery; * scheduled major orthopedic surgery, or major surgical resection of a thoracic or abdominal malignancy, or major cardiac procedure; * clinically significant depression or anxiety symptoms screened by the phq-ads (patient health questionnaire anxiety and depression scale) ≥10 exclusion criteria patient participants * estimated life expectancy \< 12 months; * unable to read, speak, and understand english; * current alcohol or other substance abuse; * severe cognitive impairment screened by the sbt (short blessed test) \>10; * acutely suicidal
effect of robot-assisted gait training on brain reorganization in hemiplegic patients

Conditions: Stroke

Summary: purpose: to evaluate the effect of robotic gait therapy for brain reorganization in hemiplegia patients.

this study designed an interventional pre-post compared clinical study. the subjects received conventional physical therapy with walkbot training (3 sessions per week for 7 weeks, 20 session). before and after intervention all subjects evaluated using diffusion tensor imaging and clinical outcome measurements.

Eligibility criteria:
inclusion criteria: * first stroke attack * within 3 months after stroke onset * supratentorial stroke * unilateral stroke exclusion criteria: * bilateral stroke * infratentorial stroke * cognitive disabilities or serious psychiatric illness. * difficulty in walking due to orthopedic problems.
study on magnetic field therapy to improve chronic lumbar pain

Conditions: Low Back Pain

Summary: objective: the objective of this study is to determine if treatment with a flex pad impregnated with static/permanent magnets that can penetrate over 70 mm may improve the quality of chronic lumbar pain with reduction of pain scores. hypothesis: the researchers hypothesis that the application of a flex pad active magnetic therapy vs. sham if utilized daily during waking hours can reduce back pain and/or radicular pain. the null hypothesis is that treatment of subjects with chronic back pain with exposure to static/permanent magnetic fields have no measurable effect on chronic back pain scores and will be equal to the underlying placebo.

design: this is a double-blind, randomized, placebo-controlled study which will consist of two treatment groups. treated subjects will receive a static/permanent magnetic flex pad with a nominal strength of less than 1000 gauss. control subjects will receive physically identical flex pad without magnet with a nominal surface field strength of 0 gauss (placebo). the magnets will be contained in a pad with a velcro cover and subjects will wear the pad attached to their undergarments/skin during waking hours. dr. weintraub will examine participants initially to look for presence or absence of radiculitis, range of motion, presence of absence of spasm, etc. the primary outcome measures will be reduction of chronic low back pain in comparison with prior baseline scores. it is recognized that these changes are subjective in nature. patients will maintain their vas scores on a monthly basis and at the end of the study, individuals will return all forms and be reevaluated by dr. weintraub. they will be asked specific questions regarding pgic for bias, etc.

Eligibility criteria:
inclusion criteria: * female or male subjects age 18-80. * capable of understanding and complying with study protocols. * chronic lumbar pain for at least six months exclusion criteria: * unable to understand informed consent (mental retardation, psychosis, communicative impairment). * cardiac pacemaker or other mechanical internal devices. * tumor in the spine/history of malignancy or tumor. * pregnancy. * prior spine surgery.

Keywords: lumbar pain magnets reduce low back pain
efficacy and safety of fty720 for acute stroke

Conditions: Stroke; Vascular Accident; Cerebral Stroke; Ischemic Cerebrovascular Accident; Stroke, Acute

Summary: stroke is one of the main severe disease of public health importance. increasing evidence suggests that inflammatory mechanisms plays a significant role in stroke. so, immune targets are supposed to be an effective one. the sphingosine-1-phosphate receptor regulator fingolimod(fty720)is an effective immunology modulator which has been widely used in autoimmune disease and has been testified effective on stoke animal models.

this study will enroll 87 stroke patients who have been diagnosed with stroke and meet the inclusion criteria. after successfully meeting initial screening criteria, investigators will contact the family, explain the study, and send a consent form for their review. after that, patients will be given 0.5mg/day oral fingolimod over a course of 3 consecutive days , then investigators will make a neurofunctional assessment before and 7days, 30 days and 90days after oral fingolimod. and magnetic resonance of the brain before, 7days, 14days and 90days after oral fingolimod. furthermore 5ml intravenous blood for flow cytometry is also taken before and 1day,3days,7days after fingolimod use.

Eligibility criteria:
inclusion criteria: * age 18-80 years * clinical presentation of spontaneous intracerebral hemorrhage/ischemic stroke * mri/mra scan compatible with spontaneous intracerebral hemorrhage/ ischemic stroke * time to fty720 treatment\< 72 h from symptom onset * glasgow coma score \>6 on initial presentation or improvement to a glasgow coma score \>6 within the time frame for enrollment. * primary supratentorial ich of ≥5cc and \<30cc * toast: large-artery atherosclerosis exclusion criteria: * patients who will undergo surgical evacuation of intracerebral hemorrhage * inability to undergo neuroimaging with magnetic resonance * glasgow coma score \< 6. * baseline modified rankin scale score \>1 * primary intraventricular hemorrhage ich due to coagulopathy (pt \> 15 s or international normalized ratio \> 1.3, partial thromboplastin time \> 36) or trauma * thrombocytopenia: platelet count \<100 000 * clinically significant hepatic disease as demonstrated by history, clinical exam (ascites, varices), or laboratory findings (lfts \>2x normal, coagulopathy as described) * comorbid conditions likely to complicate therapy including but not limited to the following: a history of new york heart association class ii, iii, or iv congestive heart failure; end-stage acquired immune deficiency syndrome * pregnancy * malignancy (history of or active) * bradyarrhythmia and atrioventricular block * concomitant use with antineoplastic,immunosuppressive or immune modulating therapies * macular edema

Keywords: stroke,fingolimod(fty 720), treatment
tspo pet in the evaluation of neuroinflammation in patients with multiple system atrophy

Conditions: Multiple System Atrophy - Cerebellar Subtype (MSA-C); Multiple System Atrophy - Parkinsonian Subtype (MSA-P)

Summary: the aim of this study was to apply pet/mr techniques targeting tspo to explore the temporal and spatial alterations characterizing neuroinflammation in msa patients, and to assess its value as a biomarker for diagnostic typing, disease severity, and prognosis of msa disease.


Eligibility criteria:
inclusion criteria: * age\> 35 years old, gender is not limited; * clinically confirmed msa and clinically probable msa according to the 2022 mds msa diagnostic criteria; * all patients had been ruled out of polyq disease by genetic testing; * voluntarily participate in this study and sign the informed consent form. exclusion criteria: * pregnancy or breastfeeding; * contraindications to mri examination or inability to cooperate in completing neuroimaging examination; * previous history of other neurological disorders or presence of other organic intracranial lesions on neuroimaging that cannot be interpreted by msa, such as epilepsy, trauma, tumors, or high-grade cerebral white matter degeneration (fazekas grade 2 and above); * history of alcohol or drug abuse

Keywords: multiple system atrophy petct tspo
ultrasound and exercises in knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: the aim of this investigation is to compare the effects of continuous (cus) and pulsed (pus) ultrasound associated with a program of exercises on pain, range of motion, muscle strength, functionality, mobility and activity in patients with knee osteoarthritis. participants were randomized into five groups: group i (in the first month, continuous ultrasound was applied), group ii (in the first month, pulsed ultrasound was applied), group iii (in the first and second month, the continuous ultrasound was applied), group iv (in the first and second month, the pulsed ultrasound was applied) and group v (patients received only exercise sessions for eight weeks).

strong evidence suggests that joint exercises reduce pain and disability in patients with osteoarthritis. there is evidence that exercise is responsible for muscular strengthening and better flexibility, improved global function as well as better performance in activities of daily living (adl). there are two modes of us, continuous and pulsed. continuous us (cus) generates thermal effects by stimulating the process of tissue regeneration, changing cell membrane permeability and increasing intracellular calcium, while pulsed us (pus) mainly produces non-thermal effects to increase tissue metabolism, enhance fibrous tissue extensibility and elevate pain threshold

Eligibility criteria:
inclusion criteria: to be included in the study, participants needed to suffer knee osteoarthritis with osteoarthritis levels 2 - 4 according to kellgren-lawrence grade12, be aged between 50 and 75 years and suffer knee pain and functional disability for at least three months, according to the criteria of the american college for rheumatology (acr)13. participants from both genders were included. the kellgren and lawrence grading of knee osteoarthritis is as follows: none (0), doubtful (1), minimal (2), moderate (3) and severe (4). the acr criteria of knee osteoarthritis are as follows: * using history and physical examination: knee pain and three of the following - over 50 years old; less than 30 minutes of morning stiffness; bone tenderness; bone enlargement; no palpable warmth of synovial. * using history, physical examination and radiographic findings: knee pain and one of the following - over 50 years old; less than 30 minutes of morning stiffness; crepitus on active motion; and osteophytes. * using history, physical examination and laboratory findings: knee pain and five of the following - over 50 years old; less than 30 minutes of morning stiffness; bone tenderness; bone enlargement; no palpable warmth of synovial; crepitus on active motion; esr \<40 mm/h; rheumatoid factor \<1: 40; synovial fluid sign of osteoarthritis. exclusion criteria: * participants were excluded if they had cancer, diabetes, symptomatic hip osteoarthritis, or used antidepressants, anti-inflammatory medications or anxiolytics during six months prior to enrollment.

Keywords: osteoarthritis, knee ultrasonic therapy exercise therapy randomized controlled trial.
lean project: weight loss and appetite suppression

Conditions: Weight Loss

Summary: the primary aim is to examine whether the intake of phospholean is effective in aiding a cohort of women in losing weight. participants taking the supplement will have significantly greater improvement in study outcomes than those taking the placebo.

participants will be randomized to either a control or treatment group taking the dietary supplement containing a soy lecithin-derived n-oleoyl-phosphatidyl-ethanolamine (nope) and caffeine free green tea-derived epigallocathchin gallate (egcg) whose trade name is phospholean. the outcome is to determine the effects on indices of weight loss and appetite suppression. participants will return at 6, 12, and 16 weeks for clinical measures.

Eligibility criteria:
inclusion criteria: * 30-45 years, women, overweight or obese class i, premenopausal, maintain current diet and exercise regimen exclusion criteria: * pregnant or planning to become pregnant, currently have or history of cancer, heart disease, anemia, diabetes, depression

Keywords: green tea weight women
neural changes in stroke patients during challenging walking tasks.

Conditions: Stroke

Summary: for stroke patients, a challenging, unfamiliar, and more difficult task may increase the likelihood of brain activation to stimulate recovery. pedal walking and walking with eyes-covered are both difficult and challenging tasks for stroke patients. the investigators intend to study the biomechanics and neural mechanisms of challenging pedal walking and walking with eyes covered. stroke participants will wear electroencephalogram electrode caps and perform three tasks: walking on a flat surface for 60 seconds, walking on pedal for 60 seconds, and walking with eyes covered for 60 seconds.

stroke participants will wear a 32-lead electroencephalogram electrode cap (zhentai technology company, xi 'an, china), first walk on a flat ground for 60 seconds, rest for 2 minutes, then walk on the pedal for 60 seconds, rest again for 2 minutes, and walk for 60 seconds with eyes-covered.

Eligibility criteria:
inclusion criteria: * first-time occurrence of stroke confirmed by computed tomography or magnetic resonance imagingclinical diagnosis of stroke * disease duration of more than 14 days， less than 1 year * able to walk independently but with a lingering abnormal gait exclusion criteria: * lesions accumulate in the brainstem * lesions accumulate in the cerebellum * impaired vision * severe cognitive impairment

Keywords: electroencephalography gait rehablitation challenging task
a phase ii study of subcutaneously injected pd-l1 antibody asc22 in chronic hepatitis b patients

Conditions: Chronic Hepatitis b

Summary: the objective of this study is to evaluate the safety and efficacy of asc22 in the treatment of chronic hepatitis b after single and multiple drug administration.

the study consists of two parts: the asc22 single-dose iia study and the asc22 multi-dose iib study. the iia study consists of 3 cohorts of 0.3mg/kg, 1.0mg/kg and 2.5mg/kg, and the iib study consists of 2 cohorts of 1.0mg/kg and 2.5mg/kg. the objective is to evaluate the safety, tolerance and efficacy of asc22 in patients with chronic hepatitis b (chb), and to provide a guidance for the determination of dosage regimen.

Eligibility criteria:
inclusion criteria: 1. 18-65 years old (including boundary value), gender unlimited； 2. chronic hepatitis b patients with clear diagnosis of hematology, etiology and clinical (for example: hbsag positive for more than 6 months); 3. hbv-dna turns negative after treatment with nucleoside (acid) drugs; 4. cohort1-5:hbsag≤ 10000 iu/ml; cohort6: hbsag≤ 100 iu/ml; 5. hbeag negative; 6. the fertile female subjects or the fertile male subjects agreed to take contraceptive measures from 7 days before the first administration until 24 weeks after the end of the administration cycle of asc22. the serum pregnancy test of fertile female subjects must be negative within 7 days before the first administration. exclusion criteria: 1. patients with hepatitis a, hepatitis c (hcv rna\>15iu/l), hepatitis d or hiv infection; patients with other active infections (e.g., respiratory tract infection, urinary tract infection and herpes simplex, cytomegalovirus, epstein-barr virus); 2. fibrosis stage: cirrhosis, portal hypertension, or advanced fibrosis (defined as fibroscan≥9.5kpa or arfi≥1.81m/sec or fibrosis-4 (fib-4)≥3.25 or metavir f≥3); 3. liver cancer patients or blood afp\>1×uln; 4. cohort1-5：patients who received interferon therapy within 6 months before the first administration; cohort6: patients who received interferon therapy before the first administration; 5. patients receiving immunosuppressive therapy within 3 months before the first administration (except interferon); 6. the investigator judges that the participants are not suitable for this study.

Keywords: chronic hepatitis b (chb) pd-l1 fc fusion protein injection
regn5381 in adult participants with uncontrolled hypertension

Conditions: Uncontrolled Hypertension

Summary: this study is researching an experimental drug called regn5381 (called "study drug"). the study is focused on uncontrolled hypertension (high blood pressure despite being on one or more antihypertensive drugs). the aim of the study is to see how effective the study drug is in reducing blood pressure. the study is designed as a 2-part study with participants initially enrolling in part a. part b of the study will commence and enroll the remaining study participants. the study is looking at several other research questions, including: * what side effects may happen from taking the study drug * how much study drug is in the blood at different times * whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)


Eligibility criteria:
key inclusion criteria: 1. adults with sbp ≥130 mm hg and sbp ≤180 mm hg at both screening and randomization visit, as described in the protocol 2. ≥ 40 and ≤85 years on a stable regimen of ≥1 anti-hypertensive therapy for at least 1 month at the time of screening or ≥30 and \<40 years on a stable regimen of ≥3 anti-hypertensive therapies for at least 1 month at the time of screening key exclusion criteria 1. heart rate \>100 bpm as described in the protocol 2. body mass index \>45 kg/m2 as described in the protocol 3. glomerular filtration rate (gfr) \<30 ml/min/1.73m2 at screening as described in the protocol 4. aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≥3x upper limit of normal (uln) as described in the protocol note: other protocol-defined inclusion/exclusion criteria apply

Keywords: high blood pressure systolic blood pressure (sbp)